Pfizer started the study of mRNA flu vaccine
On Monday Pfizer Inc (PFE.N) said that it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker
On Monday Pfizer Inc (PFE.N) said that it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech .
Conducted in the United States, the early-stage vaccine trial will be tested the in healthy adults ages 65- 85.
Kathrin Jansen, head of vaccine research and development at Pfizer said, “The COVID-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA. Influenza remains an area where we see a need for vaccines,”.
The study will test the safety and immune responses of the vaccine, compared to another FDA-approved influenza vaccine.
